The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•9 March 2026•

1 min read

uniQure Shares Surge 26% on Major Analyst Upgrades and Bullish Price Targets

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1RBC Capital upgraded uniQure to Outperform, raising the price target from $11 to $35.

2Wells Fargo set an ambitious price target of $60 for the stock with an Overweight rating.

Shares of uniQure (NASDAQ:QURE) surged over 26% following a wave of optimistic analyst upgrades and significantly higher price targets. RBC Capital upgraded the stock to "Outperform," raising its price target from $11 to $35, citing strong potential in the company's pipeline. Wells Fargo set an even more ambitious price target of $60, maintaining an "Overweight" rating on the gene therapy specialist. Market sentiment was further bolstered by the departure of a key official from the FDA, which is expected to ease the regulatory path for its Huntington's disease treatment. The company's progress in gene therapy development remains a primary driver for the recent institutional confidence. These combined factors indicate a robust outlook for uniQure as it navigates critical clinical and regulatory milestones.